ReviewFrontiers in immunology2026
Macrophage-centered immune-fibrotic persistence in endometriosis and adenomyosis: non-hormonal immunopharmacological targets.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Endometriosis and adenomyosis are commonly managed through endocrine suppression, analgesia and surgery, yet these approaches do not fully explain persistent pain, recurrence, fibrotic remodeling or variable treatment response. A growing body of immune and single-cell evidence supports a complementary view in which hormone-permissive tissue injury licenses macrophage-centered inflammatory, fibrotic and neuroimmune programs. This mini review reframes both disorders as related, but not identical, immune-fibrotic conditions and identifies tractable immunopharmacological nodes. We discuss macrophage plasticity, monocyte recruitment, cytokine and chemokine amplification, inflammasome signaling, TGF-β-driven fibrosis, oxidative and metabolic stress, neuroimmune pain signaling and targeted delivery. We argue that non-hormonal therapy should not be developed simply as an alternative to hormonal suppression. Instead, it should be tested as a phenotype-guided strategy that matches dominant immune-fibrotic programs to mechanism-based interventions while preserving reproductive safety. This framework highlights the need for biomarker-informed patient selection, compartment-specific endpoints and early attention to fertility-compatible translational design.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.